ライフサイエンスコーパス: mitral

1 s highest in patients who underwent isolated mitral (2.18; 95% CI, 1.71-2.77) and mitral + aortic val

2 Linear lesions included 14 mitral (4 RF/2 RF+PF/8 PF), 34 left atrium roof (12 RF/2

3 ndrome with significant serositis and severe mitral and aortic valve regurgitation, controlled with a

4 Importantly, moderate or severe mitral and tricuspid regurgitation also decreased (33.7%

5 yed a central role in guiding the procedure (mitral and tricuspid valve repair, left atrial appendage

6 Glomerular and mitral and tufted cell responses were sparse and locally

7 tion in the mouse olfactory bulb (OB), where mitral and tufted cells (MTCs) form parallel output stre

8 channels from the mouse olfactory bulb (OB), mitral and tufted cells (MTCs).

9 ription factor, Tbx21, which is expressed by mitral and tufted cells in the mature OB.

10 Odor features represented by ensembles of mitral and tufted cells were overlapping but distinct fr

11 Principal cells in the olfactory bulb (OB), mitral and tufted cells, play key roles in processing an

12 ry pathways that finely tune the activity of mitral and tufted cells, the principal neurons, and regu

13 lineage plays a role in the connectivity of mitral and tufted cells, the projection neurons in the m

14 n atrioventricular, single tricuspid, single mitral, and 2 atrioventricular valves was 56% (95% confi

15 them with the principal neurons of the bulb, mitral, and tufted cells.

16 Mitral annular calcification (MAC) is associated with ca

17 fornia) TMVR in annuloplasty rings or native mitral annular calcification (MAC).

18 ), mitral valve-in-ring (MViR), and valve-in-mitral annular calcification (ViMAC) outcomes has not be

19 nce of AMCC, aortic valve calcification, and mitral annular calcification as well as quantified AMCC

20 difference in aortic valve calcification and mitral annular calcification between patients with and w

21 al repairs with annuloplasty rings or severe mitral annular calcification who are poor surgical candi

22 scatheter mitral valve replacement in severe mitral annular calcification with a dedicated prosthesis

23 We aimed to evaluate the impact of mitral annular calcium (MAC) score on the development of

24 MAC (mitral annular calcium score >0) was present in 35 (33.7

25 ction are typically normal, whereas isolated mitral annular dilation and inadequate leaflet adaptatio

26 ection fraction, global longitudinal strain, mitral annular relaxation velocity, mitral E/e' ratio, l

27 y mitral inflow velocity and early diastolic mitral annular velocity (E/e') was associated with poore

28 , each unit decrease in peak systolic septal mitral annular velocity (Septal S') indicating poorer le

29 leaflet prolapse, marked leaflet redundancy, mitral annulus disjunction (MAD), a larger left atrium a

30 the papillary muscles and inferobasal wall, mitral annulus disjunction, and systolic curling have be

31 ative estimates of left ventricular mass and mitral annulus e' velocity (median absolute deviation of

32 solated mitral (2.18; 95% CI, 1.71-2.77) and mitral + aortic valve surgery (1.85; 95% CI, 1.33-2.58)

33 These findings suggest that a long muscular mitral-aortic discontinuity could predispose to the deve

34 In 2016 we identified, at myectomy, muscular mitral-aortic discontinuity in 5 young patients with obs

35 We report, for the first time, muscular mitral-aortic discontinuity in HCM.

36 ndings and assess the prevalence of muscular mitral-aortic discontinuity in obstructive HCM.

37 Muscular mitral-aortic discontinuity was identified in 28 (26%) p

38 sed overview of the role of multislice CT in mitral assessment prior to intervention.

39 an alternative for patients with degenerated mitral bioprostheses, failed surgical repairs with annul

40 ting pregnancy and suffering from failure of mitral bioprosthesis or annuloplasty.

41 Mitral block determined by pacing was achieved in 51 out

42 ion of GCaMP6 reporters allowed us to access mitral cell (MC) and superficial tufted cell (sTC) subpo

43 Here, we hypothesize that mitral cell ensembles form synchronized microcircuits th

44 n the apical dendritic compartments of large mitral cell ensembles in vivo We show that infra-slow pe

45 Furthermore, tufted and not mitral cell responses to odor mixtures become more linea

46 ; able to modulate the firing pattern of the mitral cells (M/TCs).

47 hibitory interneurons and the output neurons mitral cells (MCs) and tufted cells (TCs).

48 oth dendrites of the principal glutamatergic mitral cells (MCs) form reciprocal dendrodendritic synap

49 Mitral cells (MCs) showed more diverse changes in respon

50 , which are densely innervated by excitatory mitral cells (MCs), would show broad chemosensory tuning

51 ed to broadly inhibit activity in excitatory mitral cells (MCs).

52 aging in acute slices reveals that groups of mitral cells assemble into microcircuits that exhibit co

53 ssory olfactory pathway, projection neurons (mitral cells) display infra-slow oscillatory discharge w

54 Here, we show that AOB projection neurons (mitral cells) form parallel synchronized ensembles both

55 , olfactory circuits, in which glomeruli (or mitral cells) in the olfactory bulb synapse with neurons

56 tivity indicates functional coupling between mitral cells.

57 In patients with AF with mitral disease and no rheumatic disease, the percentage

58 ent AF (group 1; 59 males; 60+/-11 years; 91 mitral disease-related AF, 30 nonmitral disease-related

59 e association between comorbidity burden and mitral E velocity (proportion mediated 19%-35%), E/e' ra

60 lammation was also associated with increased mitral E velocity, E/e' ratio, and tricuspid regurgitati

61 95% CI, -3.1 to -0.03 mL/m2]; P = .045), and mitral E/e' ratio (from 13.8 to 12.3 vs from 13.4 to 13.

62 strain, mitral annular relaxation velocity, mitral E/e' ratio, left ventricular end-systolic and end

63 hree patients, all diagnosed with infectious mitral endocarditis, were diagnosed by microscopy, PCR-b

64 stroke, and device dysfunction (MR grade >1, mitral gradient >6 mm Hg, left ventricular outflow tract

65 The primary end point was the mean mitral gradient at peak exercise 12 months after repair.

66 +/-1.9 mm Hg versus 3.1+/-1.1 mm Hg; P=0.67) mitral gradients after leaflet resection and leaflet pre

67 owed excellent position and condition of the mitral implants without evidence for thrombosis, endocar

68 al cholesterol, left ventricular mass index, mitral inflow E/A ratio, and pulmonary vein AR duration

69 function, and a greater ratio between early mitral inflow velocity and early diastolic mitral annula

70 Achieving bidirectional mitral isthmus (MI) block using radiofrequency catheter

71 is revealed HFO current dipoles close to the mitral layer and unit firing of mitral/tufted cells was

72 Intentional laceration of the anterior mitral leaflet (LAMPOON) is an effective adjunct to tran

73 to April 2018, the area between the anterior mitral leaflet and aortic valve was inspected at myectom

74 We first fit these three mitral leaflet constitutive laws and two chordae tendine

75 s involved in fibromyxomatous changes in the mitral leaflet tissue have not been elucidated.

76 uscular discontinuity displaced the anterior mitral leaflet toward the apex in most young patients, w

77 At echocardiography, the anterior mitral leaflet was longer in patients with than those wi

78 e constitutive laws for dynamic behaviour of mitral leaflets and chordae under physiological conditio

79 paper, three different constitutive laws for mitral leaflets and two laws for chordae tendineae are s

80 Standard criteria for posterior mitral line block may not distinguish block from pseudob

81 y was to examine these standard criteria for mitral line block with endocardial and epicardial activa

82 In 56 patients, posterior mitral line was performed using radiofrequency ablation.

83 tal day (P)7 and P30 murine aortic (AoV) and mitral (MV) heart valves uncovered distinct subsets of m

84 and risk factors for PPM implantation after mitral or aortic valve surgery.

85 onary artery bypass grafting, and/or aortic, mitral or tricuspid valve surgery in Ontario, Canada, be

86 Left ventricular end-diastolic dimension and mitral peak early filling velocity-to-early diastolic an

87 veins and create 5 right atrial (PF(LD)), 6 mitral (PF(HD)), and 6 roof lines (radiofrequency+PF(HD)

88 days (median), 224 (44%) underwent invasive mitral procedure.

89 equately powered randomized trial, repair of mitral prolapse with either leaflet resection or leaflet

90 th severe MAC using an anatomically designed mitral prosthesis.

91 remodeling in patients with chronic primary mitral regurgitation (CPMR).

92 fibrillation (AF) complicating degenerative mitral regurgitation (DMR) a debated indication for surg

93 rial enlargement is frequent in degenerative mitral regurgitation (DMR), but its link to outcomes rem

94 ecific subgroups of patients with functional mitral regurgitation (eg, disproportionate versus propor

95 HR: 2.9; 95% CI: 1.5 to 5.4; p < 0.001), and mitral regurgitation (HR: 5.0; 95% CI: 1.5 to 17.1; p =

96 in some but not all patients with secondary mitral regurgitation (MR) and heart failure (HF).

97 gradient >=10 mm Hg and significant residual mitral regurgitation (MR) as >= moderate.

98 ) repair has become the standard therapy for mitral regurgitation (MR) due to degenerative diseases,

99 (5.3%), mitral stenosis (MS) in 234 (4.5%), mitral regurgitation (MR) in 1114 (21.3%, primary in 746

100 Two distinct pathways can lead to functional mitral regurgitation (MR) in patients with chronic heart

101 Mitral regurgitation (MR) is a common valvular heart dis

102 ral valve repair (TMVr) for the treatment of mitral regurgitation (MR) is a complex procedure that re

103 Mitral regurgitation (MR) is a complex valve lesion that

104 s with symptomatic HF and 3+ to 4+ secondary mitral regurgitation (MR) on maximally-tolerated medical

105 Etiology, mechanisms, and survival of mitral regurgitation (MR) plus hemodynamically-significa

106 echocardiographic parameters when evaluating mitral regurgitation (MR) severity.

107 outcomes of AKI in patients with significant mitral regurgitation (MR) undergoing transcatheter valve

108 be overestimated in patients with secondary mitral regurgitation (MR) when using LV ejection fractio

109 ic patients with either primary or secondary mitral regurgitation (MR) who were at high or prohibitiv

110 n (TR) may affect prognosis in patients with mitral regurgitation (MR).

111 Secondary mitral regurgitation (SMR) occurs in the absence of orga

112 quantitative assessment of severe secondary mitral regurgitation (sMR) reflect the lacking link of t

113 tients with heart failure (HF) and secondary mitral regurgitation (SMR).

114 y for Heart Failure Patients With Functional Mitral Regurgitation [COAPT]; NCT01626079).

115 AR, and 167 (14%) had AR + MR (9% functional mitral regurgitation [FMR] [84% nonischemic] and 5% orga

116 ation [FMR] [84% nonischemic] and 5% organic mitral regurgitation [OMR] [62% degenerative]).

117 y for Heart Failure Patients With Functional Mitral Regurgitation [The COAPT Trial] [COAPT]; NCT01626

118 y for Heart Failure Patients With Functional Mitral Regurgitation [The COAPT Trial]; NCT01626079).

119 p < 0.0001) and after further adjustment for mitral regurgitation and pacemaker/defibrillator (HR: 0.

120 is preferable over replacement for rheumatic mitral regurgitation but is not available to the vast ma

121 ) is a recent percutaneous approach to treat mitral regurgitation by placement of MC in the center of

122 tion and preservation for surgical repair of mitral regurgitation caused by prolapse.

123 r mitral valve repair (MitraClip) for severe mitral regurgitation from 2007 to 2013 as part of the EV

124 nts with heart failure and 3 to 4+ secondary mitral regurgitation from the perspective of the US heal

125 dient was 7 mm Hg, most patients (96.7%) had mitral regurgitation grade <=1 (+) and were in New York

126 ether FQs can increase the risk of aortic or mitral regurgitation has not been studied.

127 Despite the prevalence of mitral regurgitation in the elderly population, however,

128 Patients were enrolled in the MIDA (Mitral Regurgitation International Database) registry, w

129 Mitral regurgitation is frequently associated with ventr

130 Mitral regurgitation occurs from leaflet coaptation fail

131 raphic algorithm was implemented for grading mitral regurgitation severity during the screening proce

132 ent depression (all p < 0.0001) but not with mitral regurgitation severity or ejection fraction.

133 One hundred four patients with degenerative mitral regurgitation surgically amenable to either leafl

134 Mitral regurgitation was <=2+ in all the cases and mean

135 At 12 months, moderate mitral regurgitation was observed in 3 subjects in the l

136 l number of patients with severe symptomatic mitral regurgitation who are at too high of a risk to un

137 14) with moderate-severe or severe secondary mitral regurgitation who remained symptomatic despite ma

138 ion in patients with HF and severe secondary mitral regurgitation who remained symptomatic despite ma

139 h HF and moderate-severe or severe secondary mitral regurgitation who remained symptomatic despite ma

140 ng 551 patients with HF and severe secondary mitral regurgitation who were alive at 1 month, those ra

141 nts with moderate-severe or severe secondary mitral regurgitation with transcatheter mitral valve rep

142 y for Heart Failure Patients With Functional Mitral Regurgitation) demonstrated that edge-to-edge tra

143 n (eg, disproportionate versus proportionate mitral regurgitation) is key to the success of new devic

144 y for Heart Failure Patients with Functional Mitral Regurgitation) trial among patients with heart fa

145 y for Heart Failure Patients with Functional Mitral Regurgitation) trial, 614 patients with HF with m

146 y for Heart Failure Patients with Functional Mitral Regurgitation) trial, transcatheter mitral valve

147 y for Heart Failure Patients With Functional Mitral Regurgitation) trial, transcatheter mitral valve

148 y for Heart Failure Patients With Functional Mitral Regurgitation) trial.

149 y for Heart Failure Patients With Functional Mitral Regurgitation), treatment of heart failure (HF) p

150 In patients with HF and severe secondary mitral regurgitation, a short-term change in disease-spe

151 lve repair in patients with severe secondary mitral regurgitation, and implantable cardiac defibrilla

152 ctly during ventricular systole resulting in mitral regurgitation, and it is associated with sudden c

153 ncreased left atrial pressure and stiffness, mitral regurgitation, as well as features of metabolic s

154 ery disease, heart failure, aortic stenosis, mitral regurgitation, atrial fibrillation, ischemic stro

155 rate-to-severe (3+) or severe (4+) secondary mitral regurgitation, patients treated with transcathete

156 nce and severity of coronary artery disease, mitral regurgitation, pulmonary hypertension, right vent

157 s in the COAPT trial with 3+ or 4+ secondary mitral regurgitation, selected using strict echocardiogr

158 nts with heart failure and 3 to 4+ secondary mitral regurgitation, TMVr increases life expectancy and

159 sensus Decision Pathway on the Management of Mitral Regurgitation, with some sections updated and oth

160 exhibiting grade III/IV restrictive DD with mitral regurgitation.

161 s novel valve system in patients with severe mitral regurgitation.

162 whether FQs increase the risk of aortic and mitral regurgitation.

163 , and ongoing clinical trials for functional mitral regurgitation.

164 pproach aiming to treat patients with severe mitral regurgitation.

165 nts with heart failure and 3 to 4+ secondary mitral regurgitation.

166 atheter mitral valve interventions, for both mitral repair and replacement.

167 rheumatic (n=170, 33%), postsurgical (prior mitral repair/replacement, n=245, 48%), and primary nonr

168 D), aortic regurgitation (AR) in 279 (5.3%), mitral stenosis (MS) in 234 (4.5%), mitral regurgitation

169 Prevalence of calcific mitral stenosis (MS) increases with age; however, its na

170 emporary patients with suspected significant mitral stenosis (MS) undergoing rest and treadmill stres

171 Significant residual mitral stenosis (MS) was defined as mean gradient >=10 m

172 Patients with isolated mitral stenosis often benefit from percutaneous balloon

173 ion) is associated with a risk of functional mitral stenosis.

174 niques, particularly in regard to functional mitral stenosis.

175 2.75 to 12.23; p < 0.0001), and weakly post-mitral surgery (adjusted HR: 3.69; 95% CI: 0.93 to 14.74

176 Survival markedly improved after mitral surgery (time-dependent adjusted HR: 0.43 [95% CI

177 ce migration, embolization, or conversion to mitral surgery.

178 B) transiently inhibited the excitability of mitral/tufted cells (MTCs) that relay olfactory input to

179 close to the mitral layer and unit firing of mitral/tufted cells was phase locked to HFO.

180 Mitral valve (MV) repair has become the standard therapy

181 endpoint was technical success as defined by Mitral Valve Academic Research Consortium (MVARC) criter

182 ical endpoints are reported according to the Mitral Valve Academic Research Consortium (MVARC) defini

183 The rates of Mitral Valve Academic Research Consortium-defined device

184 This review will provide an overview of mitral valve anatomy, an update on the current transcath

185 ermore, LP therapy seems to adversely impact mitral valve and biventricular function.

186 rious positional placements of the MC in the mitral valve and its impact on reducing MR.

187 at are attached to specified leaflets of the mitral valve and, subsequently, MC implants are placed i

188 primary morphofunctional abnormality of the mitral valve annulus.

189 adults with isolated severe calcific MS and mitral valve area <=1.5 cm(2) from July 2003 to December

190 Mitral valve area and transmitral gradient (TMG) were 1.

191 ventricular damage (Stage 1), left atrial or mitral valve damage (Stage 2), pulmonary vasculature or

192 cardiac development as common mechanisms to mitral valve degeneration.

193 ssisted examination for diagnosing aortic or mitral valve disease (of at least moderate severity) wer

194 ation (SMR) occurs in the absence of organic mitral valve disease and may develop as the left ventric

195 ons from patients aged over 70 years who had mitral valve disease or atrial fibrillation when compare

196 predispositions for certain diseases (i.e., mitral valve disease, atrial fibrillation and osteosarco

197 omen) consecutive patients with degenerative mitral valve disease, in whom LAVI was prospectively mea

198 ventricular systolic dysfunction, aortic or mitral valve disease, or pericardial effusion; and used

199 trial fibrillation or flutter or significant mitral valve disease.

200 sural prolapse, as well as a mixed cause for mitral valve disease.

201 g left ventricular dysfunction and aortic or mitral valve disease; FoCUS-assisted examination may hel

202 Mitral valve diseases affect ~3% of the population and a

203 ineae are selected to study their effects on mitral valve dynamics with fluid-structure interaction.

204 is associated with cardiovascular events and mitral valve dysfunction.

205 ound in patients suffering from nonsyndromic mitral valve dysplasia (MVD).

206 gical reoperation in patients with recurrent mitral valve failure after previous surgical valve repai

207 power to detect a 5-mm Hg difference in mean mitral valve gradient at peak exercise, assuming an SD o

208 At 30-day follow-up, median mean mitral valve gradient was 7 mm Hg, most patients (96.7%)

209 CT assessment of the mitral valve has developed with equal rapidity, with reg

210 Transcatheter mitral valve implantation (TMVI) is emerging as an alter

211 ns have now been established as the cause of mitral valve insufficiency, and four different missense

212 s been an increase in focus on transcatheter mitral valve interventions, for both mitral repair and r

213 The mitral valve is a complex structure with a three-dimensi

214 The mitral valve is often structurally abnormal in hypertrop

215 d during follow-up in participants with T2D (mitral valve lateral E/Em increased 0.72+/-0.12 in women

216 Intentional laceration of the anterior mitral valve leaflet to prevent LVOT obstruction (LAMPOO

217 interventions that are directed only at the mitral valve leaflets (eg, transcatheter mitral valve re

218 rably to treatments that are directed to the mitral valve leaflets or their supporting structures (eg

219 eart valve form an ensemble, with the native mitral valve leaflets secured in between, thereby abolis

220 ause annular dilatation and tethering of the mitral valve leaflets, there is a linear relationship be

221 willingness to accept risks associated with mitral valve medical devices.

222 Mean gradient across the mitral valve postprocedure was 5.7+/-2.8 mm Hg (>=5 mm H

223 prevalence of echocardiographically defined mitral valve prolapse (MVP) in the general population, t

224 Background Mitral valve prolapse (MVP) is a common heart valve dise

225 Mitral valve prolapse (MVP) is often considered benign b

226 Mitral valve prolapse (MVP) is one of the most common va

227 Mitral valve prolapse was present in 5.4%, Marfan syndro

228 es mellitus (DM), asthma, allergic rhinitis, mitral valve prolapse, collagen vascular disease, aortic

229 athy, 0.86 for cardiac amyloid, and 0.77 for mitral valve prolapse.

230 F) and from 39 patients in sinus rhythm with mitral valve regurgitation (group 2; 32 males; 59+/-12 y

231 An increase in mitral valve regurgitation was observed in 38% of patien

232 istics, procedural characteristics (residual mitral valve regurgitation, periprocedural bleeding), si

233 epair (TMVr) with MitraClip in patients with mitral valve regurgitation.

234 Mitral valve reinterventions were identified through cla

235 with atrial fibrillation and a bioprosthetic mitral valve remain uncertain.

236 >65 years of age who underwent transcatheter mitral valve repair (MitraClip) for severe mitral regurg

237 the understanding of changes occurring after mitral valve repair (MVR).

238 Transcatheter mitral valve repair (TMVr) for the treatment of mitral r

239 tension influences outcomes of transcatheter mitral valve repair (TMVr) in patients with HF with SMR.

240 l Mitral Regurgitation) trial, transcatheter mitral valve repair (TMVr) led to reduced heart failure

241 itation, patients treated with transcatheter mitral valve repair (TMVr) through leaflet approximation

242 dary mitral regurgitation with transcatheter mitral valve repair (TMVr) using the MitraClip plus guid

243 rated health status benefit of transcatheter mitral valve repair (TMVr) with MitraClip in patients wi

244 l Mitral Regurgitation) trial, transcatheter mitral valve repair (TMVr) with the MitraClip rapidly im

245 demonstrated that edge-to-edge transcatheter mitral valve repair (TMVr) with the MitraClip resulted i

246 e-sixth of patients undergoing transcatheter mitral valve repair had AKI, linked to device failure or

247 interventricular dyssynchrony, transcatheter mitral valve repair in patients with severe secondary mi

248 Guideline-directed medical therapy, surgical mitral valve repair or replacement, and, in the setting

249 Transcatheter mitral valve repair with the MitraClip in patients with

250 Transcatheter mitral valve repair with the MitraClip results in marked

251 eld has resulted in approval of edge-to-edge mitral valve repair with the MitraClip, and there are se

252 , cardiac resynchronization or transcatheter mitral valve repair), but they may derive little benefit

253 the mitral valve leaflets (eg, transcatheter mitral valve repair).

254 T2 inhibitors, vericiguat, and transcatheter mitral valve repair, all of which incrementally improve

255 orable clinical response after transcatheter mitral valve repair.

256 ts who are being evaluated for transcatheter mitral valve repair.

257 Transcatheter mitral valve replacement (TMVR) is a rapidly evolving th

258 of a percutaneous transseptal transcatheter mitral valve replacement (TMVR) system.

259 f mortality and exclusion from transcatheter mitral valve replacement (TMVR).

260 Delaying definitive mechanical mitral valve replacement and the constraints of anticoag

261 h, and 3 patients required elective surgical mitral valve replacement at 6- to 54-month follow-up.

262 to evaluate the potential for transcatheter mitral valve replacement in patients with severe MAC usi

263 I) is emerging as an alternative to surgical mitral valve replacement in selected high-risk patients.

264 Transcatheter mitral valve replacement in severe mitral annular calcif

265 Transcatheter mitral valve replacement is a novel therapeutic approach

266 ON) is an effective adjunct to transcatheter mitral valve replacement that prevents left ventricular

267 Transcatheter mitral valve replacement using aortic transcatheter hear

268 edure times (from traversal to transcatheter mitral valve replacement) were shorter, compared with th

269 te the anterior leaflet before transcatheter mitral valve replacement.

270 tract obstruction required elective surgical mitral valve replacement.

271 re both independently associated with repeat mitral valve replacement.

272 e implantation (eg, transcatheter aortic and mitral valve replacements) was further elucidated in lar

273 rial fibrillation without moderate or severe mitral valve stenosis or prosthetic mechanical heart val

274 west after coronary artery bypass grafting + mitral valve surgery (1.38; 95% CI, 1.11-1.70).

275 maker (PPM) implantation is higher following mitral valve surgery (MVS) with ablation for atrial fibr

276 alysis in patients with severe CPMR awaiting mitral valve surgery and stratified the study population

277 All patients who underwent open aortic or mitral valve surgery between January 1996 and December 2

278 Patients With Atrial Fibrillation Undergoing Mitral Valve Surgery; NCT00903370).

279 Mitral valve thickening was observed in Fabry rats using

280 ramine administration, MRA treatment reduced mitral valve thickness and proteoglycan content.

281 tion by placement of MC in the center of the mitral valve to reduce MR.

282 ten localized (for example, to the aortic or mitral valve), disease manifestations are regularly obse

283 ng are well-known causes of tricuspid valve, mitral valve, and cardiac dysfunction.

284 with atrial fibrillation and a bioprosthetic mitral valve, rivaroxaban was noninferior to warfarin wi

285 ve analysis of mitral valve-in-valve (MViV), mitral valve-in-ring (MViR), and valve-in-mitral annular

286 A comprehensive analysis of mitral valve-in-valve (MViV), mitral valve-in-ring (MViR

287 Mitral valve-in-valve (ViV) and valve-in-ring (ViR) are

288 he effective regurgitant orifice area of the mitral valve.

289 on both the fluid and solid mechanics of the mitral valve.

290 cluding the blood pool, pulmonary veins, and mitral valve.

291 with atrial fibrillation and a bioprosthetic mitral valve.

292 nts and mechanical properties for aortic and mitral valves have been studied, very little is known ab

293 lei of endothelial and interstitial cells of mitral valves in mouse.

294 oglycan expression was slightly lower in the mitral valves of MVP patients treated with MRA.

295 Subsequently, mitral valves were implanted in 10 pigs using a dedicate

296 as discordant for seven pulmonary valves, 22 mitral valves, and 21 tricuspid valves.

297 osis often benefit from percutaneous balloon mitral valvuloplasty.

298 ts with aortic VHD, the suboptimal figure in mitral VHD and late referral for valvular interventions

299 idual MS and/or MR were not infrequent after mitral ViV and ViR procedures and were both associated w

300 es to improve postprocedural hemodynamics in mitral ViV and ViR should be further explored.

301 Patients undergoing mitral ViV and ViR were enrolled in the Valve-in-Valve I

302 le analysis examining midterm outcomes after mitral ViV and ViR.